Advertisement

Contralateral breast radiation doses in breast cancer patients treated with helical tomotherapy

  • Ezgi Oymak
    Affiliations
    Division of Radiation Oncology, Iskenderun Gelisim Hospital, Hatay, Turkey
    Search for articles by this author
  • Recep Bozca
    Affiliations
    Department of Radiation Oncology, Baskent University Faculty of Medicine Adana Dr Turgut Noyan Research and Treatment Center, Adana, Turkey
    Search for articles by this author
  • Ozan Cem Guler
    Affiliations
    Department of Radiation Oncology, Baskent University Faculty of Medicine Adana Dr Turgut Noyan Research and Treatment Center, Adana, Turkey
    Search for articles by this author
  • Cem Onal
    Correspondence
    Reprint requests to Cem Onal, MD, Department of Radiation Oncology, Adana Dr. Turgut Noyan Research and Treatment Center, Baskent University Faculty of Medicine, 01120 Adana, Turkey
    Affiliations
    Department of Radiation Oncology, Baskent University Faculty of Medicine Adana Dr Turgut Noyan Research and Treatment Center, Adana, Turkey

    Department of Radiation Oncology, Baskent University Faculty of Medicine, Ankara, Turkey
    Search for articles by this author
Published:December 24, 2022DOI:https://doi.org/10.1016/j.meddos.2022.11.002

      Abstract

      We aimed to evaluate contralateral breast doses calculated with a Treatment Planning System (TPS) and verified with metal oxide semiconductor field effect transistor (MOSFET) detectors in patients with early-stage breast cancer (BC) who received helical tomotherapy (HT) after breast-conserving surgery. The dosimetric data of 30 patients (15 left-sided and 15 right-sided) with BC treated with 50.4 Gy to the whole breast and 64.4 Gy to the tumor bed in 28 fractions were analyzed. TPS doses were calculated and MOSFET doses were measured in the contralateral breast (CB) at cranial, caudal, and midpoint and 2 cm lateral to the central point. TPS and MOSFET doses were compared in the entire cohort as well as by tumor location (inner vs outer quadrant) and planning target volume of the breast (<1200 cc vs ≥1200 cc). The average doses at superior, inferior, central, and lateral points calculated with the TPS were 0.26 ± 0.15 cGy, 0.21 ± 0.09 cGy, 0.65 ± 0.14 cGy, and 0.50 ± 0.11 cGy, respectively, and were 0.37 ± 0.16 cGy, 0.34 ± 0.12 cGy, 0.60 ± 0.18 cGy, and 0.34 ± 0.15 cGy, respectively in MOSFET readings. Except for the central point, TPS-calculated doses and MOSFET readings were differed. The doses to the CB in patients with inner and outer quadrant tumors were not significantly different. In patients with large breasts, MOSFET doses were higher at superior and lateral points than TPS doses, but TPS doses were greater at inferior points. MOSFET readings were higher than TPS calculated doses in patients with inner or outer quadrant tumors in small or large breast volumes. The dose calculated by the TPS and that measured by MOSFET differed by a very small amount. The maximum dose to the CB administered at the midpoint was 1.8 Gy, as calculated using the TPS and confirmed using MOSFET detectors, in patients with early-stage BC undergoing breast-only radiotherapy with HT.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Medical Dosimetry
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Sung H
        • Ferlay J
        • Siegel RL
        • et al.
        Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 Countries.
        CA Cancer J Clin. 2021; 71: 209-249
        • Allemani C
        • Matsuda T
        • Di Carlo V
        • et al.
        Global surveillance of trends in cancer survival 2000-14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries.
        Lancet. 2018; 391: 1023-1075
        • Gu L
        • Dai W
        • Fu R
        • et al.
        Comparing Hypofractionated with conventional Fractionated Radiotherapy after Breast-Conserving Surgery for early Breast Cancer: A Meta-Analysis of Randomized Controlled Trials.
        Front Oncol. 2021; 11753209
        • Darby S
        • McGale P
        • Correa C
        • et al.
        Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10,801 women in 17 randomised trials.
        Lancet. 2011; 378:: 1707-1716
        • Andrade TRM
        • Fonseca MCM
        • Segreto HRC
        Meta-analysis of long-term efficacy and safety of hypofractionated radiotherapy in the treatment of early breast cancer.
        Breast. 2019; 48: 24-31
        • Johansen S
        • Olsen DR
        • Danielsen T
        • et al.
        Contralateral breast doses following radiotherapy of the breast and regional lymph nodes: Measurements and treatment planning calculations.
        Radiother Oncol. 2007; 82: 332-336
        • Warlick WB
        • O'Rear JH
        • Earley L
        • et al.
        Dose to the contralateral breast: a comparison of two techniques using the enhanced dynamic wedge versus a standard wedge.
        Med Dosim. 1997; 22: 185-191
        • Bagheri H
        • Farhood B
        • Mahdavi SR
        • et al.
        Measurement of the contralateral breast photon and neutron dose in breast cancer radiotherapy: A Monte Carlo study.
        J Cancer Res Ther. 2019; 15: 1018-1023
        • La Tessa C
        • Berger T
        • Kaderka R
        • et al.
        Out-of-field dose studies with an anthropomorphic phantom: comparison of X-rays and particle therapy treatments.
        Radiother Oncol. 2012; 105: 133-138
        • Tubiana M.
        Can we reduce the incidence of second primary malignancies occurring after radiotherapy? A critical review.
        Radiother Oncol. 2009; 91: 4-15
        • Marcu LG
        • Santos A
        • Bezak E.
        Risk of second primary cancer after breast cancer treatment.
        Eur J Cancer Care (Engl). 2014; 23: 51-64
        • Grantzau T
        • Overgaard J.
        Second cancers after radiotherapy for early breast cancer.
        Radiother Oncol. 2015; 115: 432-433
        • Wang R
        • Shen J
        • Yan H
        • et al.
        Dosimetric comparison between intensity-modulated radiotherapy and volumetric-modulated arc therapy in patients of left-sided breast cancer treated with modified radical mastectomy: CONSORT.
        Medicine (Baltimore). 2022; 101: e28427
        • Onal C
        • Efe E
        • Guler OC
        • et al.
        Dosimetric Comparison of Sequential vs Simultaneous-integrated Boost in Early-stage Breast Cancer Patients treated with Breast-conserving Surgery.
        In Vivo. 2019; 33: 2181-2189
        • Onal C
        • Sonmez A
        • Arslan G
        • et al.
        Dosimetric comparison of the field-in-field technique and tangential wedged beams for breast irradiation.
        Jpn J Radiol. 2012; 30: 218-226
        • Dicuonzo S
        • Patti F
        • Luraschi R
        • et al.
        Comparing TomoHelical and TomoDirect in postmastectomy hypofractionated radiotherapy after immediate breast reconstruction.
        Phys Med. 2021; 90: 66-72
        • Alterio D
        • La Rocca E
        • Volpe S
        • et al.
        Hypofractionated proton therapy in breast cancer: where are we? A critical review of the literature.
        Breast Cancer Res Treat. 2022; 192: 249-263
        • Donovan EM
        • James H
        • Bonora M
        • et al.
        Second cancer incidence risk estimates using BEIR VII models for standard and complex external beam radiotherapy for early breast cancer.
        Med Phys. 2012; 39: 5814-5824
        • Santos AM
        • Marcu LG
        • Wong CM
        Risk estimation of second primary cancers after breast radiotherapy.
        Acta Oncol. 2016; 55: 1331-1337
        • Johansen S
        • Danielsen T
        • Olsen DR.
        Estimated risk for secondary cancer in the contra-lateral breast following radiation therapy of breast cancer.
        Acta Oncol. 2008; 47: 391-396
        • Offersen BV
        • Boersma LJ
        • Kirkove C
        • et al.
        ESTRO consensus guideline on target volume delineation for elective radiation therapy of early stage breast cancer.
        Radiother Oncol. 2015; 114: 3-10
        • Zhao H
        • He M
        • Cheng G
        • et al.
        A comparative dosimetric study of left sided breast cancer after breast-conserving surgery treated with VMAT and IMRT.
        Radiat Oncol. 2015; 10: 231
        • Michalski A
        • Atyeo J
        • Cox J
        • et al.
        A dosimetric comparison of 3D-CRT, IMRT, and static tomotherapy with an SIB for large and small breast volumes.
        Med Dosim. 2014; 39: 163-168
        • De Rose F
        • Cozzi L
        • Meattini I
        • et al.
        The potential role of intensity-modulated proton therapy in the Regional Nodal Irradiation of Breast Cancer: A Treatment Planning Study.
        Clin Oncol (R Coll Radiol). 2020; 32: 26-34
        • Paganetti H
        • Depauw N
        • Johnson A
        The risk for developing a secondary cancer after breast radiation therapy: Comparison of photon and proton techniques.
        Radiother Oncol. 2020; 149: 212-218
        • Clarke M
        • Collins R
        • Darby S
        • et al.
        Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials.
        Lancet. 2005; 366: 2087-2106
        • Kelly CA
        • Wang XY
        • Chu JC
        Dose to contralateral breast: a comparison of four primary breast irradiation techniques.
        Int J Radiat Oncol Biol Phys. 1996; 34: 727-732
        • Xu XG
        • Bednarz B
        • Paganetti H.
        A review of dosimetry studies on external-beam radiation treatment with respect to second cancer induction.
        Phys Med Biol. 2008; 53: R193-R241
        • Alzoubi AS
        • Kandaiya S
        • Shukri A
        • et al.
        Contralateral breast dose from chest wall and breast irradiation: local experience.
        Australas Phys Eng Sci Med. 2010; 33: 137-144
        • Horner-Rieber J
        • Forster T
        • Hommertgen A
        • et al.
        Intensity Modulated Radiation Therapy (IMRT) With Simultaneously Integrated Boost Shortens Treatment Time and is Noninferior to Conventional Radiation Therapy followed by sequential Boost in Adjuvant Breast Cancer Treatment: Results of a Large Randomized Phase III Trial (IMRT-MC2 Trial).
        Int J Radiat Oncol Biol Phys. 2021; 109: 1311-1324
        • Wojcieszynski AP
        • Olson AK
        • Rong Y
        • et al.
        Acute toxicity from Breast Cancer Radiation using Helical Tomotherapy with a Simultaneous Integrated Boost.
        Technol Cancer Res Treat. 2016; 15: 257-265
        • Starkschall G
        • St George FJ
        • Zellmer DL
        Surface dose for megavoltage photon beams outside the treatment field.
        Med Phys. 1983; 10 (906–010)
        • Consorti R
        • Petrucci A
        • Fortunato F
        • et al.
        In vivo dosimetry with MOSFETs: dosimetric characterization and first clinical results in intraoperative radiotherapy.
        Int J Radiat Oncol Biol Phys. 2005; 63: 952-960
        • Jornet N
        • Carrasco P
        • Jurado D
        • et al.
        Comparison study of MOSFET detectors and diodes for entrance in vivo dosimetry in 18 MV x-ray beams.
        Med Phys. 2004; 31: 2534-2542
        • Dias AG
        • Pinto DFS
        • Borges MF
        • et al.
        Optimization of skin dose using in-vivo MOSFET dose measurements in bolus/non-bolus fraction ratio: A VMAT and a 3DCRT study.
        J Appl Clin Med Phys. 2019; 20: 63-70
        • López-Tarjuelo J
        • Bouché-Babiloni A
        • Morillo-Macías V
        • et al.
        In vivo dosimetry in intraoperative electron radiotherapy: microMOSFETs, radiochromic films and a general-purpose linac.
        Strahlenther Onkol. 2014; 190: 1060-1065
        • Kinhikar RA
        • Pai R
        • Master Z
        • et al.
        Characterization of metal oxide field-effect transistors for first helical tomotherapy Hi-Art II unit in India.
        J Cancer Res Ther. 2009; 5: 284-289
        • Qin S
        • Chen T
        • Wang L
        • et al.
        Angular dependence of the MOSFET dosimeter and its impact on in vivo surface dose measurement in breast cancer treatment.
        Technol Cancer Res Treat. 2014; 13: 345-352